Nicholas C Nicolaides

US Patent:

6576434, Jun 10, 2003

Filed:

Feb 13, 2001

Appl. No.:

09/623624

Inventors:

Kenneth J. Holroyd - Plymouth Meeting PA
Roy C. Levitt - Plymouth Meeting PA
W. Lee Maloy - Plymouth Meeting PA
Jamila Louahed - Plymouth Meeting PA
Mike McLane - Plymouth Meeting PA
Nicholas C. Nicolaides - Plymouth Meeting PA
Yuhong Zhou - Plymouth Meeting PA
Qu Dong - Plymouth Meeting PA

Assignee:

Genaera Corporation - Plymouth Meeting PA

International Classification:

G01N 3353

US Classification:

435 721, 435 71, 435 72, 435 724

Abstract:

A new gene in the calcium-activated chloride channel family has been discovered that is induced by L-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and cystic fibrosis. A method for the identification and use of small molecule inhibitors of this gene and its products to treat these disorders has also been discovered.

US Patent:

6576468, Jun 10, 2003

Filed:

Nov 7, 2000

Appl. No.:

09/708200

Inventors:

Nicholas C. Nicolaides - Boothwyn PA
Luigi Grasso - Philadelphia PA
Philip M. Sass - Audubon PA

Assignee:

Morphotek, Inc. - Exton PA

International Classification:

C12N 1585

US Classification:

435455, 435 6, 435 721, 435440

Abstract:

Dominant-negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into mammalian cells new cell lines with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation or introduction of mutations by chemical mutagens. These methods are useful for generating novel and highly active antimicrobial molecules as well as superior antimicrobial agents from pre-existing chemicals. These methods are also useful for generating cell lines expressing novel antimicrobials that are useful for pharmaceutical manufacturing.

US Patent:

6602850, Aug 5, 2003

Filed:

Jun 16, 2000

Appl. No.:

09/596377

Inventors:

Roy Clifford Levitt - Ambler PA
Luigi Grasso - Philadelphia PA
Nicholas C. Nicolaides - Boothwyn PA
Kenneth J. Holroyd - Collegeville PA

Assignee:

Genaera Corporation - Plymouth Meeting PA

International Classification:

A61K 3816

US Classification:

514 12, 514 2, 514 8, 514826, 514885

Abstract:

This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 173. The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.

US Patent:

6610477, Aug 26, 2003

Filed:

Jun 6, 1995

Appl. No.:

08/465679

Inventors:

William A. Haseltine - Washington DC
Steven M. Ruben - Brookeville MD
Ying-Fei Wei - Berkeley CA
Mark D. Adams - Rockville MD
Robert D. Fleischmann - Gaithersburg MD
Claire M. Fraser - Potomac MD
Rebecca A. Fuldner - Barnesville MD
Ewen F. Kirkness - Olney MD
Craig A. Rosen - Laytonsville MD
Bert Vogelstein - Baltimore MD
Kenneth W. Kinzler - Bel Air MD
Nicholas C. Nicolaides - Boothwyn PA
Nickolas Papadopoulos - Brookline MA

Assignee:

Human Genome Sciences, Inc. - Rockville MD
The Johns Hopkins University - Baltimore MD

International Classification:

C12Q 168

US Classification:

435 6, 436 94

Abstract:

The present invention discloses three human DNA repair proteins and DNA (RNA) encoding such proteins and a procedure for producing such proteins by recombinant techniques. One of the human DNA repair proteins, hMLH1, has been mapped to chromosome 3 while hMLH2 has been mapped to chromosome 2 and hMLH3 has been mapped to chromosome 7. The polynucleotide sequences of the DNA repair proteins may be used for therapeutic and diagnostic treatments of a hereditary susceptibility to cancer.

US Patent:

6645492, Nov 11, 2003

Filed:

May 4, 2001

Appl. No.:

09/848585

Inventors:

Roy Clifford Levitt - Ambler PA
W. Lee Maloy - Lansdale PA
Nicholas C. Nicolaides - Media PA

Assignee:

Genaera Corporation - Plymouth Meeting PA

International Classification:

C07K 1628

US Classification:

4241391, 4241411, 4241431, 4241441, 514885, 514826, D24110

Abstract:

A C to T DNA variation at position in exon of the human Asthma Associated Factor (AAF1) produces the predicted amino acid substitution of a methionine for a threonine at codon of AAF1. When this substitution occurs in both alleles in one individual, it is associated with less evidence of atopic allergy including asthma, fewer abnormal skin test responses, and a lower serum total IgE. Thus, applicant has identified the existence of a non-asthmatic, non-atopic phenotype characterized by methionine at codon when it occurs in both AAF1 gene products in one individual.

US Patent:

6656736, Dec 2, 2003

Filed:

Feb 21, 2001

Appl. No.:

09/788657

Inventors:

Nicholas C. Nicolaides - Boothwyn PA
Philip M. Sass - Audubon PA
Luigi Grasso - Philadelphia PA
Bert Vogelstein - Baltimore MD
Kenneth W. Kinzler - Bel Air MD

Assignee:

The Johns Hopkins University - Baltimore MD
Morphotek, Inc. - Exton PA

International Classification:

C12N 1574

US Classification:

435483, 4352542

Abstract:

Yeast cells are mutagenized to obtain desirable mutants. Mutagenesis is mediated by a defective mismatch repair system which can be enhanced using conventional exogenously applied mutagens. Yeast cells with the defective mismatch repair system are hypermutable, but after selection of desired mutant yeast strains, they can be be rendered genetically stable by restoring the mismatch repair system to proper functionality.

US Patent:

6716603, Apr 6, 2004

Filed:

Oct 16, 2002

Appl. No.:

10/270595

Inventors:

Kenneth J. Holroyd - Plymouth Meeting PA
Roy C. Levitt - Plymouth Meeting PA
W. Lee Maloy - Plymouth Meeting PA
Jamila Louahed - Plymouth Meeting PA
Mike McLane - Plymouth Meeting PA
Nicholas C. Nicolaides - Boothwyn PA
Yuhong Zhou - Plymouth Meeting PA
Qu Dong - Dresher PA

Assignee:

Genaera Corporation - Plymouth Meeting PA

International Classification:

C12N 1512

US Classification:

435 691, 536 235, 435 711, 435 712, 4353201, 435325, 435471, 4352523, 43525411

Abstract:

A new gene in the calcium-activated chloride channel family has been discovered that is induced by IL-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and cystic fibrosis. A method for the identification and use of small molecule inhibitors of this gene and its products to treat these disorders has also been discovered. The invention also includes a method for diagnosing susceptibility to, and assessing treatment of atopic allergy, asthma-related disorders by measuring the level of gene expression in biologic samples using antibody specific for this protein.

US Patent:

6737268, May 18, 2004

Filed:

Nov 14, 2000

Appl. No.:

09/712691

Inventors:

Nicholas C. Nicolaides - Boothwyn PA
Luigi Grasso - Philadelphia PA
Philip M. Sass - Audubon PA

Assignee:

Morphotek, Inc. - Exton PA

International Classification:

C12N 1500

US Classification:

435325, 4353201, 435 691, 435455

Abstract:

Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. These methods are useful for generating genetic diversity within genes encoding for therapeutic antigens to produce altered polypeptides with enhanced antigenic and immunogenic activity. Moreover, these methods are useful for generating effective vaccines.